The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Product/Size:	Neomycin Sulfate Tablets, USP 500 mg
Dosage Strength:	500 mg equivalent to 350 mg Neomycin base
Lot Number(s):	CFMBX
NDC/Serial Number(s):	39822-0310-5
Expiration Date(s):	9/2022
Package Description	10 x 10 Blisters

XGen Pharmaceuticals has initiated this recall due to an Out of Specification (OOS) result reported for microbiological assay and Neomycin C for the 3-month 25°C/65% RH stability timepoint for the representative 2020 annual stability Lot CFPXF that utilized the same API Lot (CM8254) and was manufactured in the same campaign as Lot CFMBX. The OOS for microbiological assay was reported as 87.0%, outside the stability specifications of 90.0 to 120.0%. Lot CFMBX had a reported microbiological assay value of 93.4% at time of release and, although within specifications, is on the lower end of the specification and is not expected to meet its expiry dating of 24 months.

This recall is to the retail level. Initial ship date: December 10, 2020.